The occurrence of non-epileptic hyperkinetic movements in the context of developmental epileptic encephalopathies is an increasing recognised phenomenon. Identification of causative mutations provides an important insight into common pathogenic mechanisms that cause both seizures and abnormal motor control. We report biallelic loss-of-function CACNA1B variants in six children from three unrelated families presenting with a complex and progressive neurological syndrome. All affected individuals presented with epileptic encephalopathy, severe neurodevelopmental delay (often with regression), and a hyperkinetic movement disorder. Additional neurological features included postnatal microcephaly and hypotonia. Five children died in childhood or adolescence (mean age of death, 9 years), mainly due to secondary respiratory complications. CACNA1B encodes the pore-forming subunit of the pre-synaptic neuronal voltage-gated calcium channel Cav2.2/N-type, crucial for SNARE-mediated neurotransmission, particularly in the early postnatal period. Biallelic loss-of-function variants in CACNA1B are predicted to cause disruption of Ca 2+ influx, leading to impaired synaptic neurotransmission. The resultant effect on neuronal function is likely to be important in the development of involuntary movements and epilepsy. Overall, our findings provide further evidence for the key role of Cav2.2 in normal human neurodevelopment.
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Main Text
The developmental and epileptic encephalopathies (DEE) are a heterogeneous group of complex disorders characterised by severe early-onset seizures that are typically refractory to medication and associated with neurodevelopmental delay, regression and often multiple co-morbidities. 1, 2, 3 To date, advances in nextgeneration sequencing have facilitated the identification of over 150 monogenic causes of DEE. A broad range of pathophysiological processes have been identified, including disturbance of synaptic function, impaired neurotransmitter release, ion channelopathies, dysregulation of gene transcription, abnormal DNA repair, peroxisomal defects, mitochondrial dysfunction, impaired transporter activity and defective cell signalling and adhesion. 1 The majority of mutations implicated in DEE occur in genes widely expressed throughout the central nervous system, with key roles in neuronal function. It is therefore not surprising that DEE is commonly associated with additional disease features, including neurodevelopmental delay, intellectual disability, motor difficulties, microcephaly, autistic features and behavioural issues. More recently, non-epileptic movement disorders have been increasingly recognised in individuals with DEE. 4, 5 Indeed, hyperkinetic movement phenotypes, such as dystonia and choreoathetosis, are now commonly reported in individuals with FOXG1-(MIM:164874), GNAO1-(MIM:139311), SCN8A-(MIM:600702) and STXBP1-(MIM: 602926) related epilepsy-dyskinesia syndromes. [6] [7] [8] [9] We report the identification of biallelic CACNA1B variants in six children from three families presenting with DEE associated with a severe hyperkinetic movement disorder (Figure 1a-c) . Over the last decade, we have recruited 494 children with DEE of unknown aetiology for detailed endophenotyping and molecular genetic investigation. Of these, 61 had a prominent non-epileptic hyperkinetic movement disorder (Table S1 ) with dystonia, choreoathetosis, or generalised dyskinesia. Molecular genetic studies were approved by the local ethics committee (REC 13/LO/0168) and written informed consent was obtained from all participating families. Through multigene panel testing and whole exome or whole genome sequencing, an underlying genetic cause was identified in 20 of these individuals with DEE-dyskinesia phenotypes (Table S1 ).
Within the cohort of 41 unsolved cases, we identified a consanguineous family of Pakistani origin (first cousin parents) with 3 similarly affected children presenting with DEE and a hyperkinetic movement disorder (Family A, Table 1 , Figure 1a ). There was no history of neurological or metabolic disorders within the extended family. All children were born following an uncomplicated pregnancy and had a normal birth history. Affected individual A-II:2 had a period of normal development and by 8 months of age, he was able to sit unsupported and babbled. There were some concerns immediately prior to the onset of seizures with regards to hypotonia, poor visual fixation, nystagmus, and slowing of developmental milestones. At age 10 months, he had onset of epileptic spasms with >100 episodes per day, and electroencephalogram (EEG) Genome-wide linkage studies were undertaken in Family A (II:2, II:3, II:4) using Affymetrix 250K Sty1 SNP mapping array (Affymetrix, Inc., Santa Clara, CA). Genotype data was processed with Genomestudio (Illumina Inc.) and subsequently analyzed using both homozygosity mapper and manually in Microsoft
Excel. 10 Eight common regions of homozygosity (>2Mb) were initially identified ( (GenBank: NM_00013379; c.1343+5G>A) (GRCh37/hg19) ( Table S5 ). The TSHB variant was predicted to be benign by multiple in-silico programs. The DDP7 variant was predicted to be a polymorphism in
MutationTaster with minimal effect on splicing (MaxEnt Scan, NN Splice, human splicing finder [HSF] ). The CACNA1B variant, a homozygous 1bp deletion predicted to cause a frameshift and premature truncation, was predicted to be deleterious. The variant was absent in gnomAD, 1000 genomes, Exome Variant Server (EVS), and in-house exomes (N=250). In the ExAC database, CACNA1B is predicted to be extremely intolerant of loss-of-function, with a pLi score of 0.98. 11 Direct Sanger sequencing was performed, confirming whole exome sequencing findings, with appropriate segregation of the mutation in the family (Figure 1a) .
Unaffected sibling (A-II:1) was not sequenced. Whole exome sequencing data from individual A-II:4 was also probed for 154 DEE-related genes, but no potentially pathogenic variants were identified (Tables S6,7 ).
The remaining affected individuals in the epilepsy cohort were screened for CACNA1B variants by either analysis of available whole exome/genome data or through targeted CACNA1B sequencing with a custom amplicon array (TruSeq). No further cases were identified. We submitted the variant to GeneMatcher and requested collaborating research groups to probe their whole exome and genome datasets (Table S8) .
Through these routes, we identified two further families with biallelic CACNA1B variants.
A second British family with two affected children (Family B, Figure 1b ) harbouring compound heterozygous variants in CACNA1B was identified from the UK10K Genome project. 12 Table 1) . Both boys were born to non-consanguineous parents of European descent with no pertinent family history, both born after an uneventful antenatal and birth history. Affected individual B-II:1 had pre-existing developmental delay prior to onset of epilepsy at age 2.5 years, with regression of previously acquired skills before the onset of epilepsy. He had a number of different seizure types including myoclonic, focal and generalised tonic-clonic (GTC) seizures, which were refractory to multiple anti-seizure medications.
A complex hyperkinetic movement disorder, characterised by dystonic posturing, choreoathetosis and dyskinesia emerged at 2.5 years. The movement disorder was drug-resistant, and associated with frequent exacerbations, leading to significant impairment of daily living activities and quality of life. His younger brother (Individual B-II:2) had a similar presentation, with severe developmental delay, before the onset of epilepsy at age 21 months. Epilepsy was refractory to conventional anti-seizure medications. EEG abnormalities were seen as a burst-suppression pattern in sleep and high amplitude multifocal spike and wave activity when awake. (Figure 1f,g ). At age 21 months, he developed a prominent complex hyperkinetic movement disorder with features of dystonia, choreoathetoid movements, nonepileptic myoclonus and hand-wringing stereotypies. Both children had additional neurological features including microcephaly, hypotonia, visual impairment and severe cognitive difficulties. Both died, at age 17 years and 5 years respectively, from secondary respiratory complications.
A third family with a single affected proband (Family C, Figure 1c ) was identified through GeneMatcher. 13 A homozygous variant (c. 1147 C>T, p. Arg383*, Chr9:140850226) in CACNA1B was identified through a commercial clinical exome and confirmed on Sanger sequencing (Figure 1c) . The proband (C-II:1) of
Bulgarian origin was adopted, and familial segregation studies were not possible. This variant was located within an area of extended SNP homozygosity (Table S9) . A variant in MMACHC (GenBank: NM_015506.2, c.
506T>C, p. Ile169Thr, Chr1:45974544) was also identified but was excluded as the proband's serum homocysteine and urine organic acids were normal and multiple in-silico programs predicted the variant to be benign (Table S10) . No other candidates were identified from the clinical exome, despite targeted analysis of 117 DEE genes ( Table S11) Figure   S3 ). Now aged 6 years, she has developed microcephaly, hypotonia, severe intellectual disability, and is fed via gastrostomy ( Table 1) .
We have identified biallelic loss-of-function variants of CACNA1B in six children from three families with DEE associated with a severe hyperkinetic movement disorder. Figure S4) . [21] [22] [23] The expression pattern, especially in the basal ganglia and cerebellum, may bear relevance to the observed clinical manifestations associated with genes encoding calcium channel subunits, 24 given that all reported affected individuals had epilepsy and hyperkinesia as a major part of their clinical phenotype. 616172), GOSR2 (progressive myoclonic epilepsy MIM: 614018), SYT-1 (early-onset dyskinesia and intellectual disability) and SNAP25 (epilepsy and intellectual disability).
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CACNA1B is postulated to play a role in early brain development, as supported by the expression profile of Cav2.2. 20 Cav2.2 knockout murine models manifest a number of neurodevelopmental abnormalities including abnormal locomotor activity and memory impairment. 44 Future models of Cav2.2 dysfunction will be integral in further understanding the neurodevelopmental role of this protein.
In summary, we report six affected individuals with biallelic loss-of-function variants in CACNA1B, and a neurodevelopmental disorder characterised by developmental and epileptic encephalopathy, postnatal microcephaly and a complex hyperkinetic movement disorder. Identification of further cases will provide more insight into the spectrum of neurological diseases associated with CACNA1B variants, as well as potential genotype-phenotype correlations. The identification of CACNA1B further expands genetic heterogeneity in severe childhood epilepsy-dyskinesia syndromes.
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